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ABSTRACT
Selective Disruption of the Blood-Brain Barrier by
Photochemical Internalization
by
Michelle Jie Zhang
Dr. Steen Madsen, Examination Committee Chair
Associate Professor o f Health Physics
University o f Nevada, Las Vegas
Failure to eradicate infiltrating glioma cells using conventional treatment regimens
results in tumor recurrence and is responsible for the dismal prognosis o f patients with
glioblastoma multiforme (GEM). This is due to the fact that migrating glioma cells are
protected by the blood-brain barrier (EBB) which prevents the delivery o f most anti
cancer agents. The overall objective o f this work was to evaluate the ability of
photochemical internalization (PCI) to selectively disrupt the EBB in rats. This will
permit access o f anti-cancer drugs to effectively target infiltrating tumor cells, and
potentially improve the treatment effectiveness for malignant gliomas.
PCI treatment, coupling the macromolecule Clostridium perfringens (C lp) epsilon
prototoxin with AlPcSza-photodynamic therapy (PDT), was performed on non-tumor
bearing inbred Fischer rats. T2-weighted and TI-weighted post-contrast magnetic
resonance imaging (MRI) scans were used to evaluate the extent o f BBB disruption
which was inferred from treatment-induced edema and contrast volumes.
The PCI effect in rat brain was found to be dependent on light fluence,
photosensitizer concentration. C lp prototoxin concentration and administration route.

Ill

Selective disruption o f the BBB by PCI was observed for intraperitoneal administration
of 1:100 stock dilutions of Cl p prototoxin and photosensitizer concentrations and light
fluences o f I mg/kg and 1 J respectively. Single modality treatments consisting of PDT
or C lp resulted in only minimal damage to the BBB.
PCI was found to be highly effective for inducing selective and localized disruption
of the BBB. The extent o f BBB opening peaked on day 3 and was completed restored by
day 18 after PCI.
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CHAPTER 1

INTRODUCTION
I . I Malignant Gliomas
According to the Central Brain Tumor Registry o f the United States (CBTRUS)
2005-2006 statistical report, there were 43,800 new adult cases o f brain tumors diagnosed
in 2005. 20,500 o f these cases were malignant with 12,700 deaths estimated in 2007.
Gliomas represent 40% of all primary brain tumors, contributing up to 78% o f all
malignant brain tumor cases. Due to the large number o f patients with malignant gliomas
and the continued poor prognosis, it is important to study the essential factors that limit
the treatment effectiveness for malignant gliomas and evaluate the efficacy o f methods
that specifically target these factors.
1.1.1

Origin o f Gliomas

Gliomas are primary brain tumors that arise from glial cells. The central nervous
system (CNS) has four types of glial cells: (1) ependymal cells, which line the cavities of
the CNS and make up the walls o f the ventricles, with functions related to the
cerebrospinal fluid (CSF); (2) astrocytes, the largest and most common o f glial cells: the
slender cytoplasmic extensions o f astrocytes end in “feet” like processes that wrap around
capillaries, and chemicals secreted by astrocytes are responsible for maintaining the
special permeability characteristics o f endothelial cells that line the capillaries; (3)
oligodendrocytes, having fewer processes than astrocytes, are responsible for the

myelination o f neuronal axons; (4) microglia, or phagocytic cells, the least numerous and
smallest glial cells in the CNS. These cells are capable o f migrating through neural tissue
and act as a janitorial service by swallowing up waste products and pathogens (Martini,
2006).
A glioma either develops from a single type o f glial cell such as astrocytes to form
astrocytoma, or contains cells from multiple lines o f glial cells such as oligoastrocytoma.
Since all glial cells are responsible for providing support and nutrients to neurons,
maintaining homeostasis, forming myelin, destroying pathogens and dead neurons, and
participating in signal transmission in the nervous system, the formation o f malignant
gliomas in patients seriously damages their quality o f life. Since the number o f glial cells
in the CNS greatly exceeds neurons (by approximately ten times), the probability of
glioma formation is relatively high.
1.1.2

Classification o f Malignant Gliomas

Based on various histological features accompanied by genetic alterations, malignant
gliomas are classified as grade II, III or IV by the World Health Organization (WHO),
corresponding to increased tumor aggressiveness. Moderate proliferation and invasion are
usually associated with grade II malignant gliomas. Patients diagnosed with grade II
gliomas have a survival range o f 5-10 years. The degree of tumor cell proliferation and
invasion are increased in grade III gliomas, with a median patient survival o f 2-3 years.
In addition, angiogenesis which refers to a physiological process involving the growth o f
new blood vessels from pre-existing vessels is initiated at this stage. Angiogenesis
increases the aggressiveness o f tumor cells by supplying them with more oxygen and
nutrients through the newly formed blood vessels. Further differentiation o f brain tumor

cells results in grade IV malignant gliomas, which exhibit significant increases in
proliferation, invasion, angiogenesis and necrosis. The median survival o f patients with
grade IV gliomas is 12 months (Fumari et al., 2007).
1.1.3

Invasion Property o f Gliomas

The potential clinical benefits of understanding the biological basis o f glioma
proliferation, invasion, angiogenesis and necrosis cannot be overstated. Although
invasion is a common threat in all grades o f malignant gliomas, the biological
mechanisms involved in this process are not fully understood and continue to be a subject
of active study. The most frequent route o f invasion o f glioma cells occurs along white
matter tracts and basement membranes o f blood vessels. In addition, glioma cells have
also been found to grow around neurons in the gray matter and to spread along the
subpial space (Louis, 2006). The subject o f ongoing studies is to determine the reasons
that favor such preferential infiltration. One possible explanation involves the integrin
receptors that are overexpressed in malignant glioma cells. These specific glioma cell
surface receptors (aiPi, a^Pi, aePi, UvPs) interact with extracellular matrix molecules
tenascin, fibronectin, laminin, and vitronectin, respectively. These result in alterations o f
the cellular cytoskeleton which is primarily responsible for controlling cell movement.
With an altered cytoskeleton, cell locomotion is potentially promoted to yield infiltrated
glioma cells. In summary, glioma cell invasion is most likely due to a dynamic interplay
between cell-extracellular interactions, cell-cell adhesion, remodeling o f the extracellular
matrix, and cell motility (Louis, 2006).

1.1.4

Glioblastoma Multiforme

Glioblastoma multiforme (WHO grade IV) is the most eommon and biologieally
aggressive malignant glioma. It eontributes up to 50% o f all malignant gliomas aeeording
to the CBTRUS 2005-2006 report data (Chamberlain and Kormanik, 1998). Patient
prognosis is poor Avith median survival approaehing 12 months. GBM is eomposed of
poorly differentiated neoplastie eells and eharaeterized by vaseular proliferation, neerosis,
uneontrolled eellular proliferation and diffuse infiltration. In partieular, the diffuse
infiltrative nature o f GBMs makes them extremely diffieult to treat by eonventional
methods.
1.1.5 Treatments for GBM
Several novel therapeutie strategies for the treatment o f GBM have been developed in
reeent years. Surgery still remains the primary treatment method. The extent o f surgieal
tumor resection is the most important faetor determining length o f survival. Clinieal data
has shoAvn that patients Avith malignant gliomas who undergo a eomplete tumor reseetion
generally do better than those with partial tumor reseetion (Liu et al., 2008). Although a
number o f teehniques have been attempted to improve the extent of tumor reseetion, the
overall pereentage o f patients who are suitable for eomplete tumor reseetion is limited by
the loeation o f tumors in eloquent regions o f the brain. Therefore patients with residual
and measurable disease after definitive surgery are not uneommon.
Adjuvant therapies eonsisting o f ionizing radiation and ehemotherapy are often
preseribed immediately after surgery in order to eliminate residual glioma eells. New
teehniques in radiotherapy are under aetive study with the goal o f improving therapeutie
effieaey while redueing toxieity. For example, aeeelerated radiotherapy sehemes are

actively being investigated. They have the advantage of shortening treatment times and
decreasing tumor repopulation with less total radiation dose. Hyperfractionation
radiotherapy which seeks to improve treatment efficacy by increasing the total dose of
radiation while maintaining the total treatment time is under active study, as is
stereotactic radiosurgery, which has the benefit o f a high degree o f dose conformity to the
target volume (Liu et al., 2008). Finally, radiosensitizers have been tried in a number of
clinical trials without much success due to toxicity-related complications. Although
overall survival rates have not improved significantly with these advances in radiotherapy,
quality o f life has improved due to a reduction in radiation-induced toxicity.
Notwithstanding the recent discovery o f Temozolomide (TMZ), standard
chemotherapeutic regimens have been relatively ineffective against malignant gliomas.
Recent studies consisting o f TMZ and radiation have shown that this treatment regimen
may be beneficial for GBM patients, resulting in improved overall survival (OS) and
time-to-progression (TTP) (Liu et al., 2008). For example, Stupp et al. (2005) conducted
a randomized phase III study of 573 patients with newly diagnosed GBM to receive
radiotherapy (60 Gy) plus continuous daily TMZ at 75 mg/m^ followed by six cycles of
adjuvant TMZ at 150-200 mg/m^ days 1-5 every 28 days. The overall survival o f patients
receiving radiation and TMZ was improved to 14.6 months compared to 12.1 months
with radiotherapy (60 Gy) alone. Another randomized phase II study by Athanassiou et al.
(2005) involving 130 GBM patients using TMZ and radiation followed by a dose-intense
adjuvant schedule of 150 mg/m^ on day 1-5 and 15-19 every 28 days, resulted in TTP of
10.8 months compared to 5.2 months and increased I-year OS o f 56.3% compared to
15.7% in patients receiving radiation alone.

Even with substantial improvements in conventional treatments consisting o f surgery,
radiation therapy and chemotherapy, the prognosis for patients with malignant gliomas
has not improved significantly over the past four decades. Although complete removal of
the bulk tumor is possible with current available techniques, patients continue to relapse.
This is due to the aggressive infiltrating nature o f malignant gliomas: many glioma cells
have already infiltrated 2-3 cm into the surrounding normal brain at the time o f bulk
tumor resection. These infiltrative tumor cells are well embedded in brain tissues,
supplied with nutrients and oxygen by the normal brain vasculature and consequently,
also protected by the blood-brain barrier (BBB) which prevents any harmful substances
from entering the brain. Few anti-cancer drugs can effectively cross this barrier to target
the infiltrating tumor cells. Failure to eradicate infiltrating glioma cells inevitably results
in tumor recurrence and further treatments are usually palliative in scope. Therefore,
destruction o f infiltrating tumor cells is the most crucial step for curing malignant
gliomas. This cannot be accomplished until methods are developed to: (1) deliver drugs
across the BBB, or (2) selectively disrupt this protective barrier.

1.2

The Blood-Brain Barrier

Since the neural activity of the central nervous system (CNS) requires precise
homeostasis o f the neural microenvironment, protection from toxic substances circulating
in the bloodstream, and efficient nutrient delivery and waste removal, the BBB has
evolved at the critical interfaces where blood comes into contact with neural tissues to
create and maintain the optimal environment for the CNS.

The BBB is formed by tightly connected brain capillary endothelial cells (Figure 1).
Substantially different than those found in peripheral microvessels, the endothelial cells
lining the brain vessels are connected by much tighter junctional complexes to
completely seal the paracellular spaces and form a continuous physical barrier between
the CNS and blood circulation (Abbott, 2005). Both the lumen-facing (luminal, apical)
and the brain-facing (abluminal, basal) membranes o f the endothelium are made up of
phospholipid bilayers lacking fenestrations. The luminal and abluminal membranes o f the
capillary endothelium are separated by approximately 200 nm o f endothelial cytoplasm
(Pardridge, 2005). Molecules crossing the BBB must traverse these two limiting
membranes o f the endothelium. The brain side o f the capillary endothelial cells is
completely covered by a basement membrane with the end-foot processes o f the
astrocytes closely attached to it. Pericytes are embedded in the basement membrane
between the endothelial cell and astrocyte process, making particularly close contact with
endothelial cells (Abbott, 2005). They are thought to provide structural support to the
microvasculature and are important in BBB stability (Ballabh et al., 2004). Both the
basement membrane and astrocyte foot processes allow diffusion o f molecules (Pardridge,
2005) which are free to diffuse through the brain extravascular space once successfully
across the limiting membranes.
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Figure 1. Cross section through a brain microcapillary (upper panel) and the overall
structure o f the BBB (lower panel). (Modified from: http://wwwermm.cbcu.cam.ac.uk/03006264h.htm)

The impermeability of the BBB is the result o f a number o f unique features of this
barrier. Firstly, the physical restriction imposed by tight junctions between endothelial
cells greatly reduces paracellular permeability. Additionally, the transport system
regulation o f endothelial cells limits the number and types o f molecules that undergo
transcellular transport. Lastly, the metabolic activity o f endothelial cells, with powerful
enzymes metabolizing many potentially harmful substances, adds to the difficulties faced
by molecules trying to penetrate the BBB.
1.2.1

The Physical Barrier: Tight Junctions

The tight junctional complex o f the BBB is comprised o f a tight junction (TJ) and an
adherens junction (AJ). The TJ can be further grouped into three main components:
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transmembrane proteins, cytoplasmic accessory proteins, and cytoskeletal proteins
(Figure 2).
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Figure 2. Structure o f the tight junctional complex at the BBB. (Modified from ref. Huber
et al., 2001)

Three types of transmembrane proteins found at the TJ are occludin, claudins and
junction adhesion molecules (JAM). Occludin is a 65 kDa phosphoprotein which was
identified as the first transmembrane protein localized at the TJ. It consists o f four
transmembrane domains, a long COOH-terminal cytoplasmic domain, and a short NH 2 terminal cytoplasmic domain. The two cytoplasmic domains of occludin are responsible
for intracellular interaction with the cytoplasmic accessory proteins (Ballabh et al., 2004).

The other two domains o f occludin consist o f two extracellular loops including about 45
amino acids each (Gloor et al., 2001), which contribute to the regulation o f the
paracellular barrier o f the TJ. It is hypothesized that occludin is needed to regulate rather
than establish the properties o f the BBB (Wolburg and Lippoldt, 2002). Its presence at
the BBB is associated with increased electrical resistance across the barrier and decreased
paracellular permeability (Huber et al., 2001).
Claudins, the second type o f transmembrane protein o f the TJ, are a multi-gene
family consisting o f at least 24 members that have been identified in both mice and
humans. Claudins show an individually restricted expression pattern, suggesting they
contribute to tissue-specific properties o f TJs (Gloor, 2001). Compared to occludin,
claudins are significantly smaller phosphoproteins with a molecular mass of
approximately 22 kDa (Ballabh et al., 2004), but they also have four transmembrane
domains like occludin, and the COOH-terminal o f claudins binds to cytoplasmic
accessory proteins. The extracellular loops o f claudins bind homotypically to claudins on
adjacent endothelial cells to form primary paracellular seals o f the TJ (Huber et al., 2001),
which indicate the role o f claudins for establishing BBB properties.
Together, occludins and claudins form the extracellular component o f the TJ and are
both required for regulating and establishing the BBB. In the brain, claudin-1, claudin-5
and occludin have been identified in endothelial TJs as required components for the
formation o f the BBB (Ballabh et al., 2004). Studies have also revealed that the
expression o f claudin-1, claudin-5 and occludin is reduced in tumor microvessels of
GBM (Gloor et al., 2001), which explains the leaky microvasculature associated with
GBM.
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An additional transmembrane protein, junctional adhesion molecule (JAM),
localizing at the TJs belongs to the immunoglobulin (Ig) superfamily. JAM also has a
single transmembrane domain and its two extracellular Ig-like loops are formed by
disulfide bonds (Ballabh et al., 2004). The overexpression o f JAM at the TJs o f
endothelial cells increases their resistance to chemical diffusion (Gloor et al., 2001). It is
therefore suggested that JAM functionally contributes to permeability control o f the TJs.
There are a number o f cytoplasmic accessory proteins associated with the BBB
including the zonula occludens proteins (ZO-1, ZO-2 and ZO-3), cingulin, 7H6 and AF6.
ZO-1, ZO-2 and ZO-3 are structurally similar and contain three PDZ domains which help
to anchor transmembrane proteins to the cytoskeleton and hold together signaling
complexes (Ballabh et al., 2004; Matter and Baida, 2003). These specific domains o f ZO
proteins facilitate the direct binding to claudins, occludin and JAM. Cingulin interacts
with ZO-1, ZO-2, ZO-3, AF6 and others to serve as a scaffolding protein that links
cytoplasmic accessory proteins to the cytoskeleton (Huber et al., 2001).
The primary cytoskeletal protein is actin. Actin filaments, the thinnest filaments o f
the cytoskeleton, are highly versatile. They serve both structural and dynamic roles in the
cells (Huber et al., 2001). Actin has known binding sites on all ZO proteins which
establish the linkage between the TJ and the cytoskeleton. Studies have also suggested
that TJ integrity is dependent on structural organization o f actin. An Actin-disrupting
substance, such as cytochalasin D, disrupts the structure and function o f the TJ.
The adherens junction (AJ) consists o f the membrane protein cadherin that joins the
actin cytoskeleton via intermediary proteins, catenins, to form adhesive contacts between
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endothelial cells. TJ and AJ components are known to interact and influence the tight
junctional complex assembly (Ballabh et al., 2004).
Overall, the intrinsic complex structure of the TJs, along with the cytoplasmic
accessory proteins linking transmembrane proteins to the actin cytoskeleton, form a
continuous precise network o f parallel and interconnected strands o f proteins and are
arranged as a series o f multiple barriers to severely restrict the paracellular permeability
o f the endothelial cells. Therefore, circulating molecules can only gain access to the brain
via a transcellular pathway by physically crossing the brain endothelial cells.
1.2.2

Lipid-mediated Diffusion

Since endothelial cell membranes are composed o f a lipid bilayer with embedded
proteins, some small lipophilic molecules such as O 2 and CO 2 can diffuse freely through
the endothelial cells o f the BBB and enter the brain. However, most small-molecule
drugs that are used today do not cross the BBB effectively. A review o f the
Comprehensive Medicinal Chemistry (CMC) database shows that, o f over 7,000 smallmolecule drugs, only 5% demonstrate some effectiveness for a relatively limited number
o f CNS disorders. The average molecular mass o f these CNS active drugs is about 357
Da (Pardridge, 2005).
For a small-molecule drug to cross the BBB in significant amounts, the molecule
must have the following two molecular characteristics; 1) molecular mass o f less than
400-500 Da and 2) high lipid solubility. For small molecule drugs (< 400 Da) with
equivalent molecular mass, drugs with higher lipid solubility generally show increased
permeation across the BBB than the ones with lower lipid solubility. However, if the
molecular mass o f the drug is increased, the permeation o f the drug across the BBB will
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not increase in proportion to its lipid solubility. For example, experimental data indicates
that BBB permeation decreases 100-fold as the molecular mass o f the drug is increased
from about 200 to 450 Da (Pardridge, 2005). In addition, exponentially decreased BBB
permeation is associated with the addition o f each pair o f hydrogen bonds added to the
drug. Once the total number of hydrogen bonds exceeds a threshold value o f 8-10, there
is only minimal transport o f the drug across the BBB in pharmacologically significant
amounts (Pardridge, 2005; Scherrmann, 2002). This decrease in permeability is due to the
increased likelihood o f hydrogen bond formation with water which results in decreased
lipid solubility.
Although the increase in lipid solubility o f small molecule drugs is likely to increase
their penetration through the BBB, it also increases their penetration across all other
biological membranes. As the drug is rapidly removed from the blood circulation, the
total drug concentration that is encountered at the BBB is substantially decreased.
Therefore, the overall drug uptake in the brain is not always increased by increasing drug
lipophilicity.
For circulating molecules and therapeutic drugs to cross the BBB by lipid-mediated
diffusion, they must be lipid soluble and have a molecular mass less then 400 Da.
Furthermore, the fraction o f drug bound to plasma proteins must be relatively low and the
compound cannot act as a substrate for an active efflux transport system at the BBB
(Pardridge, 2005). When molecules fail to satisfy these requirements, the only method for
them to cross the BBB is via certain endogenous transport systems localized in the
endothelium.
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1.2.3

Endogenous Transport Systems

The endogenous transport systems o f endothelial cells comprising the BBB can be
broadly classified into three categories: 1) carrier-mediated transport (CMT); 2) active
efflux transport (AET); and 3) receptor-mediated transport (RMT).
In carrier-mediated transport (CMT), specific carrier proteins localized on the
endothelial membrane bind to specific organic molecules or ions and carry them across
the membranes. More than 20 carriers have been identified for transporting molecules
such as glucose, amino acids, lactic acids and nucleosides into the brain endothelium.
Some transporters are located on both the luminal and abluminal membranes o f the
endothelium, while others are located predominately on one o f the two membranes which
facilitate the directional transport o f the substances (Abbott, 2005). For example, the
GLUT-1 transporter which carries the main energy source o f the brain (glucose) across
the BBB, shows an asymmetrical surface distribution o f a 3:1 abluminal :luminal ratio
(Dobrogowska and Vorbrodt, 1999). More GLUT-1 glucose transporters localized on the
abluminal membrane o f the endothelium help to increase the amount o f glucose moving
in the blood to brain direction, thus supplying the brain with a sufficient energy source.
All forms of CMT across the endothelium have the characteristics o f specificity,
saturation limits and regulation (Martini, 2006). Each carrier protein in the endothelial
membrane will bind and transport only certain substances. For example, the GLUT-1
glucose carrier does not transport other simple sugars while lactic acid is only transported
by the MCT-1 carrier. A drug normally not transported across the BBB that is simply
coupled with a molecule that crosses the BBB by CMT is unlikely to cross the BBB by
this transport system. The rate o f transport and the amount o f substance that can cross the
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BBB by CMT is limited by the availability o f carrier proteins. The carriers are said to be
saturated when they are operating at maximum speed; the amount o f substances crossing
the BBB cannot be increased further at the saturation limit.
Active efflux transporters (AET) are capable of transporting solutes out o f brain
endothelial cells, often with consumption o f ATP (Abbott, 2005). P-glycoprotein (Pgp) is
a large (140-170 kDa) AET system at the BBB and accounts for the active efflux of
molecules in the brain to blood direction (Kemper et al., 2004). It has been established
that the Pgp active efflux transporters are present in the luminal membrane o f the brain
endothelium at high densities. Although some lipophilic drug molecules penetrate the
luminal membrane o f the brain endothelium, they are then pumped out by the Pgp efflux
transporter effectively excluding them from the brain. This efflux activity associated with
Pgp transporters explains why some therapeutic drugs show a lower BBB penetration
than is predicted from their lipophilicity (Abbott and Romero, 1996). The main function
o f AET systems similar to Pgp is to restrict a number o f potentially harmful substances
and lipophilic drugs from entering the brain (Abbott, 2005). One strategy for increasing
brain penetration o f such drugs is the development o f “co-drugs” that inhibit the AET
systems at the BBB and thereby allows increased brain penetration o f the drugs
(Pardridge, 2005).
Large molecules such as peptides and proteins are generally transported across the
BBB via the receptor-mediated transport system. In receptor-mediated transport (RMT),
the molecule undergoes a specific interaction with a membrane receptor followed by
endocytosis to internalize it to the cytoplasm o f the endothelium. There are at least three
classes o f BBB-RMT systems. First, as the name implies, the bidirectional RMT system
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causes receptor-mediated transcytosis in both the blood to brain and brain to blood
directions. For example, the transferrin receptor (TfR), a bidirectional RMT system,
transports transferrin from the blood to brain and transfers apo-transferrin from the brain
back to blood. Second, the reverse RMT system, such as the neonatal Fc receptor (FcRn),
functions only to mediate the reverse transcytosis in the brain to blood direction. Unlike
the first two receptor-mediated transcytosis systems, in the third class o f RMT system the
receptor-mediated endocytosis mediates the molecule uptake from the blood into the
endothelial cell body but this endocytosis is not followed by exocytosis into the
interstitial fluid o f the brain (Pardridge, 2005). The result of receptor-mediated
endocytosis is to internalize the circulating molecules to the endothelial cells o f the BBB
rather then across the BBB.
In summary, the main feature o f the endogenous transport systems o f the brain
endothelial cells is to limit the transcellular traffic o f circulating molecules across the
BBB. This is accomplished through: 1) the specificity and saturation limits o f carriermediated transport; 2) the restriction o f potentially harmful substances or lipophilic drug
molecules by active efflux transport; and 3) the particularly low rate o f receptor-mediated
transcytosis or endocytosis.
1.2.4 The Enzymatic Barrier
The endothelial cells o f the BBB express a range o f Phase I, II and III enzymes.
These enzymes are capable o f metabolizing many potentially harmful agents (Abbott,
2005), which further restrict the penetration o f circulating compounds at the BBB.
Several key enzymes in the endothelial cells are capable o f breaking down unwanted
blood circulating substances and brain metabolites, and thus function as a two-way
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metabolic barrier (Abbott and Romero, 1996). In the case o f some powerful enzymes,
such as monoamine oxidase, their enzymatic activity per gram tissue may approach that
o f the liver which is the primary organ involved in metabolizing circulating compounds.
In summary, the presence o f tight junctions with their complex and interconnected
structure prevents paracellular transport o f almost all circulating compounds except water
molecules. Some small molecules with molecular mass o f less than 400 Da and high lipid
solubility, may potentially diffuse through the brain endothelial cells. However smallmolecule drugs with the appropriate molecular structure and lipophilicity are generally
limited by their low therapeutic efficacy for treating CNS diseases, especially malignant
gliomas. Multiple endogenous transport systems o f the brain endothelium are capable of
transporting large molecules, but the specificity o f the transporters combined with the
low rate o f transcytosis/endocytosis greatly restrict the transcellular traffic o f these
circulating molecules. Additionally, the active efflux transporters and metabolic activity
associated with the endothelial cells further restrict potentially harmful substances and
lipophilic agents from entering the brain. Taken together, these properties o f the brain
endothelial cells have made the BBB a serious physical and metabolic barrier which
protects the brain from any unwanted substances in the blood plasma. Unfortunately this
protective barrier also prevents almost all anti-cancer drugs from crossing the BBB and
reaching the infiltrating glioma cells that have migrated from the bulk tumor.

1.3 Strategies for Delivering Drugs to the Brain
Strategies that improve the efficacy o f drug delivery to the brain are essential for the
successful treatment o f a wide variety o f CNS disorders including malignant gliomas.
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1.3.1 Trans-cranial Drug Delivery
Trans-cranial drug delivery methods that attempt to bypass the BBB include the
following three approaches: intracerebral implantation, intracerebroventricular (ICV)
infusion, and convection-enhanced delivery (CED) (Pardridge, 2005).
Intracerebral implantations have been tested in patients with malignant brain tumors.
These implants consist o f polymer wafers loaded with an anti-cancer drug. Following
surgical tumor resection, the wafer is placed in the empty surgical cavity and the
therapeutic agent (typically BCNU) diffuses through the brain parenchyma. The major
limitation of this technique is the limited diffusion capacity o f most drugs (Kemper,
2004). This is problematic since malignant glioma cells often migrate several centimeters
from the tumor resection region - a distance unlikely to be within the range o f the
diffusing drug.
Unlike endothelial cells o f the BBB, the ependymal cells that line the cavities o f the
CNS, and the walls o f the ventricles, are relatively permeable to molecules circulating in
the cerebrospinal fluid (CSF) and the interstitial space o f the brain. Therefore, the method
o f intracerebroventricular (ICV) infusion was developed to take advantage o f the
increased permeability of the ventricular system. Unfortunately, patients with brain
tumors usually do not benefit from ICV drug infusion due to the relatively small surface
o f the CSF-brain interface and the limited diffusion o f most drugs into the brain.
The common factor limiting either intracerebral implantation or the ICV infusion
method is the diffusion distance for drug penetration into the brain from the source.
Studies have shown that the concentration o f drug decreases logarithmically with
distance from the source. For example, the concentration o f a small molecule decreases
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by 90% at a distance o f only 0.5 mm from the intracerebral implantation site in rat brain
(Pardridge, 2005).
The effective drug diffusion distance in the brain can be increased to a radius o f a few
millimeters when the drug is delivered through the method o f CED. The CED approach
delivers therapeutic agents through catheters under continuous positive pressure, either
directly into the tumor or through the interstitial space around the resection cavity (Liu et
al., 2008). CED used in GBM patients causes a preferential flow o f the forced therapeutic
agents along the white matter tracts. Unfortunately, this often results in an abnormal
increase in the number o f astrocytes due to the destruction o f nearby neurons along the
white matter tracts, and thus raises concerns about the long-term effects o f this delivery
approach for patients (Pardridge, 2005).
1.3.2 Trans-vascular Drug Delivery
Despite the complex structure and impermeability of the BBB, trans-vascular drug
delivery to the brain via endothelial cells o f the BBB still represents the main route of
drug entry into the CNS. The popularity o f trans-vascular over trans-cranial drug delivery
is simply due to the favorable biological properties o f the brain capillaries.
There are over 100 billion capillaries in the human brain. Since capillaries are
separated by approximately 50 pm, the maximum diffusion distance in the brain
following trans-vascular delivery is only 25 pm. Even a molecule as large as albumin,
with a molecular mass o f 68 kDa will diffuse 25 pm in less than Is (Pardridge, 2005). In
comparison, distances between drug sources and infiltrating glioma cells are typically of
the order of several cm in the case o f intracerebral implants.
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The total length o f capillaries in the human brain is about 400 miles and the surface
area o f the brain capillary endothelium is about 20 m^ (Pardridge, 2005). The total brain
capillary surface area is about 5,000-fold larger than the blood-CSF barrier. The large
surface area o f the brain capillaries increases the probability o f drug penetration and
facilitates access of anti-cancer agents to glioma cells due to the relatively short diffusion
distances.
Taken together, the relatively short drug diffusion distances and the larger surface
area o f the brain capillaries are the main advantages of trans-vascular drug delivery
through the BBB even though the impermeability o f the BBB limits total drug uptake by
the brain. Therefore, any chemical agent or method that has the capability o f increasing
BBB permeability or temporarily disrupting the BBB structure, can rapidly increase the
efficiency o f drug delivery to the brain through the trans-vascular route.
1.3.3

Disruption o f the BBB by Osmotic Opening

Osmotic opening involves the administration o f hypertonic solutions to cause
shrinkage of the endothelial cells thereby disrupting the tight junctions to enhance the
paracellular transport o f substances through the BBB. Hypertonic solutions used for this
purpose include mannitol, arabinose, saline, and several other agents (Kemper et al.,
2004). Mannitol is the most widely investigated agent in BBB disruption. The osmotic
opening method has been shown to increase the delivery o f chemotherapeutic agents in
patients with malignant gliomas, with a subsequent decrease in morbidity and mortality
compared with patients receiving systemic chemotherapy alone (Neuwelt et al., 1994).
Unfortunately, this method tends to increase the BBB permeability in regions o f normal
brain as well as the tumor (Abbott and Romero, 1996) which can be problematic since it
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facilitates passage o f a wide variety o f circulating molecules into the brain, thus
substantially increasing the risk o f neurological effects which may outweigh the benefits
o f barrier opening.

1.4

A BBB Opening Agent: Clostridium Perfringens

Clostridium perfringens {Cl p) is a rod-shaped, gram-positive bacterium measuring
approximately 2-4 x 1-1.5 pm (Sakurai, 1995). C lp are classified into four major protein
toxins consisting o f alpha, beta, epsilon and iota toxins which are produced from a
combination o f five groups o f Cl p strains (types A-E). The Cl p toxins possess a number
o f biological activities that may result in necrosis, contraction o f smooth muscles, edema
and death. In particular, the C lp epsilon toxin and its prototoxin are o f interest in this
study, since they are known for their ability to cause widespread opening o f the BBB.
C lp Epsilon Toxin

1.4.1

Epsilon toxin (=31.4 kDa), produced by Cl p types B and D, is one o f the most potent
Cl p toxins. Administration of this toxin leads to preferential accumulation in the kidneys
and in the brain (Soler-Jover et al., 2007). Several studies support the existence of an
epsilon toxin receptor in the brain capillary endothelial membrane. Biochemical studies
on the binding o f Cl p epsilon toxin to rat brain membranes indicate a high-affmity
binding o f the toxin to specific binding sites in brain endothelial membranes. However,
the nature o f the binding sites on the endothelial membranes is not known (Zhu et al.,
2001 ).

Through binding to specific receptor sites on the brain endothelial membranes,
epsilon toxin causes severe damage to the vascular endothelium. The toxin acts very
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rapidly and in very small doses to produce a vascular endothelium defect in the brains of
mice (Buxton, 1976). The mechanism by which epsilon toxin causes vascular damage is
unknown.
Studies o f epsilon intoxication in mice brains by light or electron microscopy have
revealed some ultrastructural changes in the brain endothelium (Finnie, 1984a; Finnie,
1984b; Morgan and Kelly, 1974; Gardner, 1973). Astrocytes appeared to be particularly
sensitive to this toxin as evidenced from ultrastructural findings showing significant
astrocyte swelling, especially at the end-feet processes o f these cells. These changes were
quickly followed by evidence o f severe endothelial damage including swelling, loss of
cytoplasmic organelles with blebbing o f the luminal surface and nuclear pyknosis (Finnie,
2004).
When the epsilon toxin injures the brain capillary endothelium, there is loss o f BBB
integrity and increased vascular permeability. For example, using horse-radish peroxidase
(HRP) as a tracer, it was found that this enzyme can leak from brain blood vessels o f
mice within 1 h o f intraveous toxin administration (Morgan, 1975). Other studies using
radioactive tracers have confirmed the ability o f epsilon toxin to induce vascular leakage
in the mouse brain (Worthington and Mulders, 1975).
The increased vascular permeability o f the BBB induced by epsilon toxin leads to a
net movement o f water, electrolytes and other substances from the blood circulation into
the brain parenchyma resulting in severe cerebral edema. In edematous conditions, the
astrocytes swell prominently, particularly the processes in close contact with brain
capillary endothelial cells (Finnie, 1984a). Diffuse cerebral edema often results in
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neurological disorders, such as opisthotonus and convulsions, leading rapidly to death
(Dorca-Arévalo et al., 2008).
Cl p Epsilon Prototoxin

1.4.2

Epsilon toxin is synthesized and secreted as a non-toxic precursor prototoxin that is
converted to fully active toxin by proteolytic cleavage. Epsilon prototoxin exists in an
inactive form consisting o f one polypeptide chain o f 311 amino acids with a molecular
mass o f about 32.7 kDa (Figure 3). Upon exposure to proteolytic enzymes, especially
trypsin and chymotrypsin, epsilon prototoxin is activated by cleavage o f either amino
(NH 2 -) or carboxy (COOH-) terminal peptides o f 14 and 23 residues respectively to yield
the fully activated epsilon toxin (Soler-Jover et al., 2007).

Prototoxin:
5
10
15
Lys Glu iiMCptCmFAsx-Pro-VaFSw-Tyr-Glu-Met-Ser-Tyr Lys Ala-lle-Tyr-Asx-
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m iD i

10

Ala-liihTyr-te-Asx-ÎM -Leu-Asx Pro Leullg-ûbtFigure 3. Amino acid sequence o f Cl p epsilon prototoxin and toxin. Amino acids that are
not confirmed are in parenthesis and those not identified are labeled with a question mark.
(Modified from ref. Bhown and Habeeb, 1977)

The partial polypeptide chain compositions o f epsilon prototoxin and toxin shown in
Figure 3 reveal a common sequence o f Ala-Ile-Tyr-Asx-Val associated with both
molecules. This common sequence starting at the NHz-terminal end o f epsilon toxin is
evidence that the process o f epsilon prototoxin activation by trypsin involves the scission
o f one peptide bond between EysM-Ala,;. Therefore, the activation o f epsilon prototoxin
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to toxin is accompanied by release o f a low molecular weight (14 amino acid residues
long) peptide from the NHa-terminal end o f prototoxin (Bhown and Habeeb, 1977).
The enzymatic activation increases the toxicity o f epsilon toxin at least 1,000-fold
over the minimally toxic prototoxin (Finnie, 2004). However, in some cases a longer
exposure to proteolytic enzymes may result in further cleavage at newly exposed sites
and progressive fragmentation o f the biologically active toxin resulting in the loss of
toxicity (Bhown and Habeeb, 1977).
The activation o f epsilon prototoxin to toxin is associated with only minor
conformational changes and is neither accompanied by a large decrease in molecular
weight nor by a loss in immunochemical reactivity (Bhown and Habeeb, 1977).
1.4.3

Combined Effects o f Epsilon Toxin and Prototoxin

Soler-Jover et al. (2007) used epsilon-toxin-green fluorescence protein (epsilon-toxinGFP) and epsilon-prototoxin-GFP to track the distribution o f epsilon toxin and prototoxin
in intravenously administrated mice through direct fluorescence microscopy detection.
The results showed that both epsilon-prototoxin-GFP and epsilon-toxin-GFP accumulate
on the luminal surface o f the vascular endothelium of blood vessels in all areas o f the
mouse brain. Epsilon-toxin-GFP was also detected in the brain parenchyma surrounding
some blood vessels, suggesting that epsilon toxin, but not epsilon prototoxin, has the
ability to cross the BBB. Co-injection o f epsilon-toxin-GFP with a 10 molar excess
amount o f epsilon-prototoxin resulted in a reduced distribution or binding o f the epsilontoxin-GFP in the brain, which demonstrates the protective ability o f epsilon-prototoxin
after co-injection.
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The prototoxin, although non-active, binds to the same surface cell receptors as the
fully active toxin thus preventing the toxin from binding to the receptor sites and exerting
its toxic effects on the brain. However, the biological effects o f epsilon toxin are blocked
only in the brain, and not other tissues (Finnie, 2004).
The protection o f epsilon prototoxin seems to be relatively short lived. Nagahama and
Sakurai (1991) concluded that the inhibitory effects o f the prototoxin on the immediate
lethal activity and binding o f the toxin were present for only 10 min after the intravenous
injection of the prototoxin in mice. After ten minutes, the prototoxin appeared to have
been transported into the cells from the binding sites on the cell surface thus allowing
binding o f the toxin to the sites again. Buxton (1976) investigated the prototoxin
protection time by injecting (i.v.) formalinized epsilon prototoxin at 3, 10, 30, 100 and
750 min prior to the administration o f epsilon toxin. The protection o f prototoxin was
present from 3 min until 100 min, but was less effective by 750 min.
1.4.4 Delayed Effect o f Prototoxin on the BBB
An endothelial protein, endothelial barrier antigen (EBA), has been identified as a
marker for the BBB in the rat brain. The EBA protein is not expressed by endothelial
cells o f peripheral organs and tissues, such as the liver, intestine and heart, rather, it
appears to be localized exclusively to the luminal membranes o f the endothelial cells of
the rat brain.
Zhu et al. (2001) conducted a study to test the delayed effects o f epsilon prototoxin
(via intraperitoneal administration) on the expression o f EBA alone without subsequent
administration of epsilon toxin. The study showed a reduction in the expression o f EBA
immunoreactivity in rat brain endothelial cells following in vivo administration o f the
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inactive epsilon prototoxin. However, the relationship between the reduction in EBA
expression and the possible effect o f the prototoxin on the brain endothelium is not clear.
Results from the study also indicated that animals injected with a higher concentration of
the prototoxin showed a faster and stronger response with significant reduction in the
expression o f EBA immunoreactivity. Data from a group o f animals injected (i.p.) with a
low concentration o f epsilon prototoxin showed mild and late response where the
maximum effect was seen quantitatively 7 days post-prototoxin injection. Two animals
sacrificed at 12 h and 2 days were not significantly different from the control group, but
still showed a trend o f reduction in EBA expression. The study also demonstrated that
reduction in EBA immunoreactivity was accompanied by mild opening o f the BBB to
endogenous albumin. A progressive increase in albumin immunoreactivity was noted
from 1 to 18 h post-injection. At 24 and 48 h, albumin leakage was at its maximum. At 4
and 7 days, albumin leakage was still present but the intensity o f immunoreactivity was
reduced significantly.
In summary. Cl p epsilon toxin causes widespread brain endothelial damage leading
to severe disruption o f the BBB and cerebral edema. The biological effects o f the Cl p
epsilon toxin can be temporarily prevented by prior administration o f C lp epsilon
prototoxin due to competitive binding o f receptor sites on the endothelial membranes.
Administration o f Cl p epsilon prototoxin alone in the rat model results in a reduction o f
EBA in brain endothelial cells which is also accompanied by a mild opening o f the BBB.
Global opening o f the BBB has been observed in response to the administration of
osmotic agents or Cl p toxin and prototoxin. Unfortunately, the severe side effects
observed following widespread BBB breakdown outweigh the potential benefits.
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Therefore, methods for selective disruption o f the BBB allowing targeted drug delivery to
the diseased area o f the brain are likely to result in greater therapeutic efficacy while
minimizing toxicity to normal brain.

1.5

Photodynamic Therapy

Photodynamic therapy (PDT) is a treatment modality combining a photosensitizing
drug and light to activate the photosensitizer in an oxygen-dependent manner resulting in
oxidation o f biomolecules in the light-exposed region. PDT has been approved for the
treatment of a variety o f conditions including cancer, vascular diseases, viral infections
and age-related macular degeneration (Hogset et al., 2004). Recently, there has been a lot
o f interest in the use o f PDT for the treatment o f refractory tumors. Due to the fact that
PDT does not lead to cumulative toxicity in the patient, and there is no known maximum
cumulative dose as exists with both radiation therapy and chemotherapy (Castano, 2005),
repeated PDT treatments may be an option over conventional treatment methods. Perhaps
more importantly, PDT has a high degree o f selectivity for a number o f tumors including
gliomas.
1.5.1

Photophysics o f PDT

A photosensitizer is a drug used in PDT, which upon absorption o f light is excited to
a physical state that is capable o f inducing various reactive oxygen species which, in turn,
cause biological damage. The ground state o f the photosensitizer has paired electrons
with opposite spins in the lowest energy molecular orbital which is known as the singlet
state (Figure 4). Upon absorption o f a light quantum, an electron is excited to a
previously unoccupied orbital o f higher energy while maintaining its spin (excited singlet
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State). Depending on the amount o f energy absorbed, the photosensitizer is excited to the
first or higher excited singlet state.

Each excited state consists o f a number o f vibrational levels with increasing energy
(Figure 5). An electron in a high vibrational level o f an excited state will rapidly fall to
the lowest vibrational level o f that excited state. During this process o f vibrational
relaxation, the energy is dissipated as heat and the photosensitizer drops to its first
excited singlet state with a very short lifetime (of the order o f nanoseconds).

Photosensitizer
First Excited Triplet State fT ,)

First Excited Singlet S tate f S J

Obltai Assignment

®.®.

ISC

®. ®. =
®. Q j

Excitation

Ground Singlet State (’So)

7C

Figure 4. Representations o f the lowest singlet and triplet states o f a photosensitizer. ISC
- intersystem crossing. (Modified from ref. DeRosa and Crutchley, 2002)

The short-lived first excited singlet state can de-excite by emitting a light photon as
fluorescence or by internal conversion into heat, returning the photosensitizer to its
ground state. The fluorescence emission spectrum o f any photosensitizer depends only on
its specific electronic structure but not the light wavelength used for excitation. This
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fluorescing property o f photosensitizers can be used as a diagnostic tool for detecting
tumor cells and evaluating the effects o f treatment.
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Figure 5. Diagram o f the primary photophysical processes o f PDT. S„ - singlet states, T„
- triplet states, VR - vibrational relaxation, 1C - internal conversion, ISC - intersystem
crossing. (Modified from ref. Plaetzer et al., 2008; Calzavara-Pinton et al., 2007)

The first excited singlet state o f a photosensitizer having two unpaired electrons with
opposite spins may also undergo the process known as intersystem crossing (ISC), where
the spin o f the excited electron inverts to form the relatively long-lived (microseconds)
first excited triplet state that has electrons in a parallel spin configuration. This transition
violates the rule o f no spin change during a change o f an electronic state, however, in the
case o f macrocyclic molecules with conjugated double bond systems (u-electron system)
which are characteristic o f most photosensitizers, ISC transitions occur with high
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probability. De-excitation o f the photosensitizer triplet state directly to its singlet ground
state is also a “spin-forbidden” process, the energy loss by emission o f light is delayed in
this process, known as phosphorescence, and it is also the reason for the relatively long
photosensitizer triplet state lifetime (Castano et al., 2004; Castano et al., 2005; Plaetzer et
al., 2008).
The most important step o f the photophysical processes in PDT is the formation of
the triplet state o f the photosensitizer. A photosensitizer used in PDT is thus required to
have a high quantum yield of triplet state formation. Furthermore, the triplet state must
also have a relatively long lifetime for the relevant photochemical reactions to take place.
1.5.2 Photochemistry o f PDT
The excited triplet state of a photosensitizer can induce chemical changes in
neighboring molecules via two types o f mechanisms. Type 1 mechanisms involve
electron or hydrogen atom transfer between the excited photosensitizer and adjacent
oxygen molecules or other substrates to produce various reactive oxygen species (ROS).
For instance, the formation o f superoxide anions (O 2 ) by transfer o f an electron from the
photosensitizer to an oxygen molecule, is a frequent result o f type 1 reactions. Superoxide
can then react to produce another ROS, namely hydrogen peroxide (H2 O 2 ). At high
concentrations, hydrogen peroxide can react with superoxide anions again to form the
very reactive hydroxyl radicals ( OH). Despite the fact that superoxides are not very
reactive in biological systems, further ROS products such as hydrogen peroxide and
hydroxyl radicals can easily diffuse through biological membranes and oxidize molecules
within a cell to produce cellular damage (Plaetzer et al., 2008).
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Figure 6. Representation o f molecular oxygen’s lowest singlet and triplet states and their
corresponding potential energy curves. (Modified from ref. DeRosa and Crutchley, 2002)

The type II mechanism involves a direct energy transfer through a collision o f the
excited photosensitizer with surrounding oxygen molecules to form singlet oxygen - a
particularly damaging ROS. As shown in Figure 6, the triplet state configuration (^2~)
represents the ground state o f the oxygen molecule which has two unpaired electrons
with parallel spins in two different orbitals. The other two configurations o f molecular
oxygen,

and ’2 ^ , which represent two forms o f excited singlet states are

approximately 95 and 158 kJ/mol above the oxygen triplet state, respectively. These
potential energies correspond to quantum wavelengths o f about 1270 and 762 nm,
respectively (DeRosa and Crutchley, 2002). The second excited singlet state o f oxygen
( ' u p is short-lived, quickly de-exciting to the first excited singlet state (*A ). Since the
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transition from the

state to the

state is spin-forbidden, the oxygen 'A^ state is a

relatively long-lived and stable species.
After intersystem crossing, a triplet state o f the photosensitizer is formed with an
energy o f about 110-130 kJ/mol (Plaetzer et al., 2008). Due to the fact that the ground
state oxygen molecule exists in a triplet state configuration, it favors the reaction between
the triplet state photosensitizer and adjacent oxygen molecules. A minimum energy
transfer of about 95 kJ/mol from the triplet state photosensitizer to surrounding oxygen
molecule through collision is required to excite the triplet state oxygen to form singlet
oxygen. Concurrently, the excited triplet state photosensitizer is converted back to its
ground state which is then ready for further cycles o f excitation and generation o f singlet
oxygen. Thus, the triplet state photosensitizer must exceed this energy threshold which
equals the potential energy gap o f ’A^ state oxygen and the ground state

(approx. 95

kJ/mol) corresponding to a photon wavelength o f 1270 nm.
The singlet oxygen formation ability o f a photosensitizer is measured by its quantum
yield (O a). The quantum yield o f singlet oxygen formation o f a photosensitizer is
commonly determined by detecting the 1270 nm luminescence associated with singlet
oxygen relaxation. Almost all photosensitizers used in PDT have a high quantum yield
for singlet oxygen formation (approx. 0.3 to 0.5) (DeRosa and Crutchley, 2002).
Singlet oxygen in its excited energy state oxidizes substrates that are normally
unaffected by oxygen in its ground state. Its powerful oxidizing ability makes singlet
oxygen the primary cytotoxic agent responsible for many photobiological activities. In
particular, singlet oxygen causes membrane damage by oxidizing amino acids.
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unsaturated fatty acids and cholesterol, which are the primary constituents o f biological
membranes (Berg et ah, 2005).
Since singlet oxygen has a very short lifetime (< 0.1 millisecond) in biological
systems, its range of action is confined to approximately 10-20 nm (Castano et ah, 2004).
Therefore, only molecules and structures that are very close to the area o f singlet oxygen
production, corresponding to the area o f photosensitizer localization, are directly affected
by PDT.
It is worthwhile to note that, during the PDT process, photosensitizer molecules can
be chemically modified or even degraded by a direct attack o f singlet oxygen or other
ROS through a process termed photobleaching. Each photosensitizer molecule typically
produces 10^-10^ molecules of singlet oxygen before being degraded through
photobleaching by singlet oxygen or by some other process (DeRosa and Crutchley,
2002). Photobleaching is a necessary process in order to clear out the photosensitizer
from the biological system in a short period o f time.
Both type I and II mechanisms o f photochemical reactions in PDT can occur
simultaneously, and the ratio between these processes depends on the type of
photosensitizer used and the concentrations o f adjacent substrates and oxygen molecules.
Reactive oxygen species produced from the photochemical reactions, especially singlet
oxygen, are powerful oxidizing agents that can directly react with many biological
molecules and are thus responsible for all photobiological activities associated with PDT.
1.5.3 Types and Properties o f Photosensitizers
Most photosensitizers used in PDT today are porphyrins or porphyrin-related
compounds. A structure o f the simplest porphyrin is shown in Figure 7a. Porphyrins and
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their derivatives have the ability to absorb several wavelengths in the UV-visible region.
The long-lived triplet states of many porphyrins allow for high quantum yields of singlet
oxygen formation. Some porphyrins undergo rapid degradation in the presence o f singlet
oxygen (high photobleaching). This could be an advantage in biological systems where
rapid breakdown of the photosensitizer is necessary. Porphyrin derivatives also have
substituents in the peripheral position o f the pyrrole rings and metal ions coordinated at
the center which influence their properties including water/lipid solubility, amphiphilicity
and stability of the compounds (DeRosa and Crutchley, 2002).
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Figure 7. Chemical structures o f a) porphyrin and b) phthalocyanine. (Modified from ref.
DeRosa and Crutchley, 2002)

The first well-studied porphyrin photosensitizer used in PDT was haematoporphyrin
derivative (HpD) or Photofrin II. Despite the high triplet state and singlet oxygen
quantum yields of HpD (0.83 and 0.65, respectively) (DeRosa and Crutchley, 2002), it is
still far from the ideal photosensitizer. First o f all, the complex chemical structure o f HpD
makes it very difficult to synthesize and purify. Secondly, the absorption o f light is weak
in the red part o f the spectrum where light transmission through tissue is high. Thirdly,
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the tumor-to-tissue concentration ratio (selectivity) is poor. Finally, the long-lasting skin
photosensitivity o f HpD is a clinical disadvantage since patients may have to avoid
sunlight for as long as eight weeks (Castano et al., 2004).
In contrast, the use of 5-aminolevulinic acid (ALA) which interacts with the intrinsic
cellular heme biosynthetic pathway to produce the photosensitizer, protoporphyrin IX
(PpIX) (Figure 8), has attracted great attention due to the short photosensitivity period
after application o f ALA. ALA is hydrophilic and is taken up mainly by active transport
mechanisms in mammalian cells (Calzavara-Pinton et al., 2007). The endogenously
formed photosensitizer PpIX is remarkably sensitive to photobleaching and skin
photosensitivity lasts for only 1-2 days (DeRosa and Crutchley, 2002). Tumor-to-tissue
ratios for ALA-induced PpIX are typically around 10:1 (Berg et al., 2005) compared to 23:1 for chemically synthesized photosensitizers.

H

5-ALA

CH

IIX
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Figure 8. Chemical structures o f 5-ALA and its product PpIX. (Modified from ref. Berg
et al., 2005)

A second widely studied group o f photosensitizers is the phthalocyanines (Pc). The
phthalocyanine skeleton (Figure 7b) resembles that o f porphyrins (Figure 7a) but an extra
aromatic ring is introduced on each pyrrol group which is also linked by nitrogen atoms
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instead of the methane carbons in the porphyrins (Berg et al., 1989). The extended
conjugation o f the peripheral benzene rings in the phthalocyanine structure significantly
increases its absorption in the red region o f the spectrum (650-700 nm). This absorption
spectrum overlaps with the region o f maximum light penetration in tissues, thus
potentially improving the treatment depths o f PDT.

SO:i
SO .
Figure 9. Structure of the photosensitizer aluminum phthalocyanine dilsulphonate
(AlPcSia). (Modified from ref. Berg et al., 2005)

The photosensitizer, aluminum phthalocyanine disulfonate (AlPcS 2 a), is a
phthalocyanine derivative containing two charged sulfonate groups linked to phthalic
subunits in adjacent positions on the Pc molecule and an Al metal ion coordinated at its
center (Figure 9). The most important and distinguishable property of AlPcS 2 a is its
amphiphilicity which refers to a chemical compound possessing both hydrophilic and
lipophilic properties. Most phthalocyanine photosensitizers are lipophilic and therefore
insoluble in water, which makes them unsuitable for use in biological systems. This
problem has been solved by sulfonation and by hydroxylation o f the benzene rings in the
phthalocyanine (Berg et al., 1989). For example, while the phthalocyanine skeleton of
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AlPcS 2 a is lipophilic, the two adjacent sulfonate groups attached to the phthalocyanine
molecule contributes to its hydrophilic nature. This amphiphilic photosensitizer is
perfectly designed to localize in the cellular membrane (Maman et al., 1999). This is
achieved by inserting the lipophilic phthalocyanine skeleton o f AlPcS 2 a in the lipophilic
interior o f the cellular membrane and dissolving the sulfonate groups in the hydrophilic
outer layer o f the membrane. AlPcS 2 a molecules first localize in the cell membrane.
During endocytosis, a partial cell membrane with previously localized AlPcS 2 a molecules
pinches inward to form an endocytic vesicle and subsequently, the attached AlPcS 2 a
molecules are transported into the cell via the membrane of the vesicle.
Depending on the physicochemical properties o f photosensitizers, they can be taken
up by the cell body by endocytosis or by active or passive transport through the plasma
membrane. Different photosensitizers will localize differently inside the cell. Since the
photosensitizer-generated singlet oxygen has a very short active range in the biological
system, the overall biological damage induced by PDT is closely related to the precise
subcellular localization o f the photosensistizer.
In summary, an ideal PDT photosensitizer should exhibit the following properties: 1)
strong light absorption in the red or near infra-red part o f the spectrum in order to achieve
optimal tissue penetration and minimize the photosensitizer dose required to achieve the
desired effect; 2) high triplet state quantum yield (Oy > 0.4) and long triplet state lifetime
(>1 microsecond); 3) high photostability; 4) amphiphilicity; 5) favorable
pharmacokinetics, preferably accumulating rapidly and preferentially in diseased tissues;
6) low levels o f dark toxicity and 7) minimal side effects and rapid clearance from the
body after PDT (Castano et al., 2004; Castano et al., 2005; Plaetzer et al., 2008).
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1.5.4

PDT Light Dosimetry

Light propagation in biological tissues depends on the following four processes:
refraction, reflection, scattering and absorption. Both refraction and reflection are related
to the incident angles and can be minimized by applying the light beam perpendicular to
the interface between the two media. The scattering o f light in tissue has the most
pronounced effect on the intensity and directionality o f the light beam. Together,
refraction and scattering are the primary causes o f light attenuation in biological tissues.
For PDT on solid tumors, the effective light penetration depth is defined by the depth
where light intensity is reduced to 37% o f its initial value. For clinical treatments with
Photofrin at 630 nm, the light penetration depth is approximately 3-5 mm depending on
the tissue (Plaetzer et al., 2008).
1.5.5

Limitations and Advantages o f PDT

Although the poor penetration o f light through tissues limits PDT treatment volumes,
the use o f optical fibers for interstitial light delivery, has significantly increased the
number o f sites accessible to PDT. Even so, the poor penetration depth o f red light is a
limiting factor for the depth o f tumor necrosis achievable in a reasonable time period
(Prasmickaite et al., 2002).
The biggest advantage o f PDT is dual selectivity (DeRosa and Crutchley, 2002).
Firstly, the photosensitizer preferentially localizes in the target tissue. Secondly, the
selective light illumination in the target region further confines the photochemical
damage. PDT as a new cancer treatment tool thus allows for the possibility o f tumor
destruction with minimal effects on normal tissues through careful selection of
photosensitizers with high tumor specificity. Such specificity is important in a number of

38

applications including PDT-induced BBB disruption which may be a useful approach for
delivering drugs to brain lesions protected by the BBB.

1.6

Photochemical Internalization

Photochemical internalization (PCI) is a novel technology that is under development
for utilizing the properties o f PDT to enhance the drug delivery o f macromolecules in a
site-specific manner.
1.6.1

Limitation o f Macromolecule Therapy

Although a number o f small molecule drugs can readily enter cells, they have
relatively low therapeutic specificity primarily due to their structural limitations. In
contrast, large macromolecular drugs can easily be coupled to targeting ligands which are
able to bind to specific receptors on target cells, thus they have the potential advantage o f
exerting a higher therapeutic specificity than small molecule drugs.
Since macromolecules are taken up by the cell body through endocytosis, they have
to penetrate through the membranes o f endocytic vesicles and into the cytosol in order to
exert their full biological effects on the cell. Unfortunately, macromolecules generally do
not escape easily from endocytic vesicles and consequently, trapped macromolecules are
degraded by powerful lysosomal enzymes thereby losing their therapeutic effects. This
major limitation o f macromolecule therapy has greatly hindered the therapeutic potential
o f macromolecular drugs (Berg et al., 2006).
In order to improve the drug delivery o f macromolecules and exploit their full
therapeutic effects, a new technology (PCI) has been introduced which utilizes PDT and
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specially designed membrane localizing photosensitizers to target the membranes of
endocytic vesicles.
1.6.2 Specific Photosensitizers in PCI
Since the main target o f PCI is the membranes o f endocytic vesicles, the choice of
membrane-localizing photosensitizer is important for effective PCI. In this respect,
photosensitizers with an amphiphilic structure are the most efficient since the hydrophilic
part of the photosensitizer prevents penetration through the cellular membrane. Once the
photosensitizer is securely localized in the cell membrane, it will eventually be
incorporated into the membranes o f endocytic vesicles via the process o f endocytosis.
The photosensitizer must maintain its position within the endocytic vesicle while the
macromolecular drugs are trapped within the vesicle in order to avoid photochemical
destruction of the macromolecules.
AlPcSia is currently the most popular and preferred photosensitizer for PCI. As
detailed in section 1.5.3, AlPcSia is mainly localized in the membrane of endocytic
vesicles. Interestingly, the sulfonation state o f AlPcSn (n=l, 2, 3, 4) is important since
different states exhibit different properties. For example, Paquette et al. (1988) have
shown that cellular photosensitivity increases with decreasing AlPcSn sulfonation. This is
due to differences in the amount o f photosensitizer taken up by the cells: decreasing
sulfonation is associated with increasing lipophilicity. The biological activity o f these
photosensitizers is increased by an order o f magnitude as the number o f sulfonation
groups decreases from 4 to 2 (DeRosa and Crutchley, 2002). Not all sulfonated aluminum
phthalocyanines are preferentially localized in the vesicular membranes. For example,
tetrasulphonated phthalocyanine is mainly located in the matrix o f the endocytic vesicles
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(Berg et al., 2006). Therefore, the purity o f AlPcSza used in PCI can directly influence the
efficiency and outcome o f the PCI method.
1.6.3 Mechanisms o f PCI
While specific amphiphilic photosensitizers (e.g. AlPcSza) preferentially accumulate
in the membranes o f endocytic vesicles, upon light exposure the photosensitizer interacts
with ambient oxygen to produce singlet oxygen. Since singlet oxygen has a very short
range o f action (< 20 nm), only the area o f the vesicular membrane where the
photosensitizer is localized will be damaged by singlet oxygen-mediated reactions with
amino acids, unsaturated fatty acids and cholesterol in the membrane bilayer. Although
the exact structure o f the damaged vesicles has not yet been elucidated, the results of
vesicular membrane damage (either increased permeability or destructive opening
depending on the light fluence and photosensitizer concentration) are easily demonstrated.
The previously trapped macromolecular drugs can now be released from the endocytic
vesicles into the cytosol in a fully functional form and are free to diffuse to their intended
targets (e.g. DNA) to exert their therapeutic effects. The PCI concept is illustrated in
Figure 10.
1.6.4 Advantages o f PCI
PCI as a drug delivery technology has many advantages. I) There are no restrictions
on the size o f the molecules that can be effectively delivered, making PCI highly suitable
for a wide variety o f molecules. 2) PCI also exhibits high site-specificity, which limits the
biological effect to only illuminated areas and lowers the potential systemic side effects
o f the delivered drug. 3) PCI is a method that increases the therapeutic efficacy o f a wide
range o f macromolecules allowing for the possibility o f using lower drug doses to
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minimize morbidity. 4) PCI is well suited for combination with other modalities or
strategies for targeted drug delivery, thus increasing the potential for further therapeutic
improvements (Hogset et al., 2004).

11

111

Cytosol
Figure 10. Illustration of the PCI mechanism. M - macromolecule, S - photosensitizer.
(Modified from ref. Hogset et al., 2004)

1.7

Proposal and Hypothesis o f PCI Study in BBB Disruption

The efficacy of PCI-mediated delivery o f Cl p epsilon prototoxin for selective
opening of the BBB in inbred Fischer rats will be investigated in this study. Since the
overall objective of the proposed work is to use PCI to produce localized opening of the
BBB, only low concentrations o f C lp will be administered, i.e., concentrations
sufficiently below the threshold for BBB opening. Disruption of the BBB will be
achieved by combining sub-threshold doses of Cl p with sub-threshold PDT light
fluences, i.e., the so-called PCI effect. Magnetic resonance imaging will be used to infer
the extent of BBB disruption and to track BBB dynamics following each treatment
procedure. Specifically, edema formation and gadolinium contrast enhancement will be
used as markers for BBB disruption.
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It is hypothesized that the biologieal effeets o f the Cl p epsilon prototoxin on the
BBB will be potentiated by PCI, but only in areas of the brain exposed to adequate light
fluenees. Due to this potentiation effeet, sub-threshold C lp doses will be suffieient to
open the BBB. It is hypothesized that the low proto toxin dose will be inadequate to open
the BBB in regions where the light fluenee is insuffieient to evoke the PCI effeet.
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CHAPTER 2

MATERIALS AND METHODS
2.1 Experimental Animals
Inbred male Fischer rats (Simonsen Laboratories, Inc, Gilroy, CA) weighing about
350 g were used in this study. The animals were housed in the UNLV Animal Care
Facility. Animal holding rooms were maintained at constant temperature and humidity on
a 12-hour light and dark schedule at an air exchange rate o f 18 changes per hour. The
animal care and protocol were in accordance with institutional guidelines. All surgical
procedures were performed in this facility. For the surgical procedures, the animals were
anaesthetized with Pentobarbital (25 mg/kg i.p.). Buprenorphin (0.08 mg/kg s.c.) as a
post-operative analgesic was administered to animals following surgery and twice per
day for three days thereafter. All animals were euthanized at the end o f the study or at the
first signs of distress. The euthanasia procedure was accomplished with an overdose of
Pentobarbital (100 mg/kg i.p.). In this study, animals were subjected to one o f three
treatments: (1) PDT-only, (2) C l/7-only, or (3) PCI.

2.2

PDT-only Treatment Protocol

The photosensitizer, aluminum phthalocyanine disulphonate (AlPcS 2 a), was diluted to
1.25 mg/ml in PBS and administered (i.p.) 48 hours prior to light treatment. Animals
received photosensitizer concentrations o f 10, 5 or 1 mg/kg. At the time o f the surgical
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procedure, each animal was anesthetized with Pentobarbital and fixed in a stereotactic
frame. A skin incision was made to expose the skull and a burr hole was made manually
with a small gauge needle 1 mm posterior to the bregma and 3 mm to the right o f the
midline. A 400 pm bare flat-end quartz fiber connected to a portable diode laser was
introduced directly into the rat brain to a depth o f 5 mm below the dura. Light from the
670 nm diode laser was delivered at a fluenee rate o f 10 mW. Light fluenees o f 1, 2, 4, 9
or 26 J were investigated. Treatment times ranged from 100 s to 43 min. After treatment
was completed the optical fiber was removed and closure was done with bone wax and
sutures.
The interstitial light delivery approach described above resulted in extensive damage
to the brain and subsequently a number o f animals died soon after treatment, even with
the smallest photosensitizer/light dose combination o f 1 mg/kg and 1 J. To decrease
treatment related morbidity and mortality, surface irradiation was used throughout the
remaining light treatments. In this method, most o f the PDT treatment procedure
remained the same except that no burr hole was drilled. Instead, a skin incision was made
exposing the skull and the optical fiber was placed in contact with the surface o f the skull
at the identical coordinates used to drill the hole for the interstitial treatments. An AlPcS 2 a
concentration o f 1 mg/kg combined with light fluenee levels o f 2.5, 1 or 0.5 J were
examined for evaluating the extent o f BBB disruption in the group o f animals receiving
PDT-only treatment.
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C lp-only Treatment Protocol

2.3

Cl p epsilon prototoxin stock solution (1 mg/ml) was diluted to three different
concentrations of 1:10, 1:50 and 1:100 in PBS. Each concentration was administered (0.7
ml, i.p.) into animals for a toxicity study o f C lp epsilon prototoxin.
In addition, a method o f intracranial delivery o f Cl p prototoxin was performed for
toxicity comparison. The animal was first sedated and placed in a stereotactic frame.
Following skin incision, a small hole was made as previously described and Cl p
prototoxin (5 pi) was delivered intracranially (1.5 mm below the dura) at a speed o f 5
pl/min using a high precision automatic injector (Harvard Apparatus, Cambridge MA).
Two different C lp concentrations were investigated: 1:50 and 1:10. The toxicity and the
extent o f BBB disruption induced by different concentrations o f Cl p prototoxin with
both intraperitoneal and intracranial delivery methods were evaluated.

2.4

PCI Treatment Protocol

Based on individual evaluation o f PDT-only and Cl /?-only treatments, a
photosensitizer concentration o f 1 mg/kg AlPcSia was used in the PCI treatments. Three
light fluenees (2.5, 1 and 0.5 J) were evaluated and both C lp prototoxin delivery methods
(i.p.: 1:100 and i.e.: 1:50) were examined.
In a complete PCI treatment procedure, the animal was first injected with
photosensitizer AlPcS 2 a (1 mg/kg, i.p.). 48 hr later. C lp prototoxin was administered
either intraperitoneally or intracranially at a concentration described previously. A
surface light irradiation was given approximately 60 minutes after Cl p administration by
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using one o f the light fluenees determined earlier. The extent o f BBB disruption by the
PCI effect was evaluated and compared with PDT-only and Cl jc-only treatments.

2.5 MR Imaging
Treated animals were imaged in a 7.0 T animal MR scanner (Bruker) at the Nevada
Cancer Institute. Scans were typically acquired on days 1,3, 5, 8 and 18 post treatments.
At the beginning o f each imaging session, the animal was anesthetized in an induction
chamber connected to isoflurane gas anesthesia. After sedation, the rat was quickly set up
on the animal bed o f the MR scanner, which was also equipped with a nosecone and
tooth-bar fixation system for constant anesthesia throughout the scan. A small surface
coil was placed on top o f the target area and a T2-weighted (TR = 4200 ms; TE= 36 ms)
MR image was acquired. The rat was then removed from the scanner and administered a
Gadolinium-based contrast agent (Multihance, 0.8 ml i.p.). A T1-weighted (TR = 700 ms;
TE = 14 ms) post contrast MR image was taken 1 5 - 2 0 min after the contrast injection.
T2-weighted MR images were used for evaluating the brain edema, which is an
indirect result o f BBB disruption, induced by PDT-only, Cl ;?-only or PCI treatments.
Since water molecules have a long T2 relaxation time, which induces a very high T2
signal, edema appears bright on T2-weighted images and is therefore easily visualized.
The gadolinium-based contrast agent (Multihance) has paramagnetic properties, and
therefore develops a magnetic moment when placed in a magnetic field. A large local
magnetic field produced by this paramagnetic contrast agent can enhance the relaxation
rates of water protons in its vicinity (reduce the T1 relaxation time), leading to an
increase in signal intensity. That is the reason that Gd-based contrast agents appear bright
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on T1-weighted images. Sinee Multihance, with a moleeular weight o f 1058.2 Da, is too
large to eross the intaet BBB, any contrast enhancement evident on T1-weighted images
was taken as direet evidenee o f BBB disruption indueed by the corresponding treatment.

2.6 Data Analysis
The extent o f BBB disruption from each treatment was evaluated from the degree of
contrast enhancement observed on T1 post contrast images and from the edema volume
evident on T2 images. The qualitative analyses o f eontrast and edema volumes were
examined using MIPAV (Medieal Image Proeessing, Analysis & Visualization) software.
Both eontrast and edema volumes were first manually eontoured on eaeh T1 or T2 image
sliee. Then the total volume was caleulated automatically by the software aeeording to
the following equation: V =

*T)cm^ where Sj represents the eontrast area

eontoured on eaeh sliee and T represents the image slice thiekness (T = I.O mm was used
in all MR images aequired in this study).
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CHAPTER 3

RESULTS
3.1

Comparison o f Light Delivery Methods in AlPcS 2 a-PDT

Both interstitial and surface irradiation methods were evaluated in the PDT-only
group of animals. Different concentrations o f AlPcS 2 a combined with varying levels of
light fluenees were tested under both o f the light delivery methods and the results are
summarized in Figure 11. The top seven data bars in Figure 11 display the survival time
o f animals that received interstitial light irradiation. By decreasing the concentration of
AlPcS 2 a from 10 to 1 mg/kg and lowering the light fluenee from 26 to 1 J, survival time
after PDT treatment was increased from about 20 min at the highest level o f the
photosensitizer concentration and light fluenee combination to about 24 h for the
minimum photosensitizer and light fluenee combination. In contrast, all animals receiving
surface irradiation survived the treatment. In this study, animals that survived for at least
20 days were considered long term survivors. Long-term survival following surface
irradiation was observed for all AlPcS 2 a concentration (1 to 5 mg/kg) and light fluenee
combinations (2.5, 2, I, and 0.5 J) investigated in this study.
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Figure 11. Comparison o f animal survival after PDT using interstitial or surface
irradiation. The n values to the right o f each data bar indicate the number o f animals used
per group. The top seven data bars represent interstitial irradiation. The surface
irradiation data bar represents long-term survival o f animals (n = 16) exposed to all
photosensitizer and light fluenee combinations, including 5 mg/kg + 1 J, 1 mg/kg + 2.5 J,
1 mg/kg -f 1 J and 1 mg/kg

3.2

0.5 J.

Comparison o f BBB Disruption Induced by ALA-PDT and AlPcSaa-PDT

In a previous study, PDT treatment with a prodrug (ALA) was evaluated for inducing
BBB disruption (Hirschberg et al., 2008). A direct comparison of the extent of BBB
disruption between ALA-mediated and AlPcS 2 a-mediated PDT treatments is shown in
Figure 12. Both of the animals were treated using interstitial light delivery. One animal
was administrated 125 mg/kg (i.p.) ALA and received a light fluenee o f 17 J. The result
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of T1 post contrast MR images after ALA-PDT treatment shows only a small localized
region of contrast enhancement which indicates a minimum amount of BBB disruption
(Figure 12 a). In contrast, the animal in scan b) received only I mg/kg (i.p.) AlPcSia and
was irradiated to a light fluenee o f I J. With substantially less photosensitizer and a lower
light fluenee, the TI post contrast image shown in Figure 12 b suggests a massive BBB
disruption following PDT. This extensive BBB disruption explains the reason for the low
animal survival associated with interstitial irradiation delivery.

I
X
Figure 12. Comparison o f BBB disruption induced by ALA-PDT and AlPcSia-PDT. T Iweighted post contrast MRI scans o f rat brains were taken I day after PDT treatments, a)
ALA-PDT treatment with 125 mg/kg ALA (i.p.) and a light fluenee o f 17 J (modified
from ref. Hirschberg et ah, 2008). The image was acquired using a 3 T human scanner, b)
AlPcSia-PDT treatment with 1 mg/kg AIPcS 2 a (i.p.) and a light fluenee o f 1 J. The image
was acquired using a 7 T small bore animal scanner.
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3.3

Effects o f Photosensitizer Concentration in AlPcSia-PDT

Two different AlPcSza photosensitizer concentrations (5 and 1 mg/kg) were
administrated i.p. to two sets of animals 48 h prior to light treatment. A light fluenee o f 1
J was delivered via surface irradiation to both sets o f animals. T2-weighted followed by
Tl-weighted post contrast MRI scans were taken for each animal on days 1,3, and 8 after
PDT treatment. Both contrast and edema volumes appeared on TI post contrast and T2
images, respectively, and were calculated separately as shown in Figures 13 a and b.
As illustrated in Figures 13 a and b, there are significant decreases in both edema and
contrast volumes with decreasing photosensitizer concentrations indicating that the lower
concentration resulted in a reduced degree o f BBB disruption following PDT. The data
also show a significant reduction in both edema and contrast volumes 8 days following
treatment suggesting a gradual closing o f the BBB.
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Figure 13. a) Contrast and b) edema volumes induced by PDT with varying
photosensitizer concentrations. The animals received 5 or 1 mg/kg (i.p.) o f AlPcS 2 a prior
to light treatment (1 J, 10 mW) and were scanned on days 1, 3 and 8 following PDT
treatment. The n values listed above each data set indicate the number o f animals used to
generate the corresponding data bars.
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3.4

Effects o f Light Fluenee Level in AlPcSia-PDT

Since the lower concentration o f AlPcSia resulted in a smaller amount o f BBB
disruption, a concentration of 1 mg/kg was used in the rest o f the treatments. The effects
o f light fluenee on BBB disruption is illustrated in Figures 14 a and b.
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Figure 14. a) Contrast and b) edema volumes induced by PDT with varying light fluenee
levels. The animals received 1 mg/kg (i.p.) AlPcSia 48 h prior to light treatment. The n
values listed above each data set indicate the number o f animals used to generate the
corresponding data bars.
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As illustrated in Figures 14 a and b, the degree o f contrast enhancement and edema
formation (and hence BBB disruption) is clearly fluenee dependent: the highest light
fluenee investigated resulted in the greatest edema and contrast enhancement. Only
minimal edema and enhancement were observed at the two lower fluenees (0.5 and 1 J).
O f particular interest is the time evolution o f edema and enhancement. In both cases,
volumes peaked on day 3 indicating a delay in treatment-induced BBB response.
Thereafter, both edema and contrast volumes were observed to decrease. By day 11, only
trace amounts o f edema and contrast were observed in the 0.5 and 1 J animals, while the
high fluenee animals still demonstrated significant edema and contrast volumes.

3.5

Surviving Fraction o f Rats Following Cl p Prototoxin Exposure

Figure 15 shows the surviving fraction o f rats that received Cl p prototoxin through
either intraperitoneal (i.p.) or intracranial (i.e.) administration at various concentrations.
Animals alive after 20 days were considered long-term survivors. As shown in Figure 15,
all animals receiving the prototoxin i.e. survived. In contrast, the delivery o f C l p i o
animals via intraperitoneal injection proved to be much more toxic resulting in death of
all animals receiving a dose of 1:10. It is interesting to note that, although i.p.
administration resulted in significant mortality, no evidence o f BBB disruption was
observed on MR images. Overall, the results suggest that i.e. or i.p. injection o f C l p ai a
concentration o f 1:100 or lower is well tolerated and therefore provided the rationale for
its use in the PCI treatments.
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Figure 15. Surviving fraction of animals receiving Cl p prototoxin through different
administration routes at varying concentrations. Two administration methods were
compared: i.e. (5 pi total volume) and i.p. (0.7 ml total volume). The n value above each
data bar indicates the total number o f animals used per group.

3.6

BBB Disruption Induced by the PCI Effect

The effects of PCI on the BBB for a light fluenee o f 2.5 J are shown in Figure 16. For
comparative purposes, the effects o f PDT are also shown. The contrast (Figure 16 a) and
edema (Figure 16 b) volumes induced by the two treatment modalities were similar. In
both cases, edema and contrast enhancement peaked on the fourth day post-treatment and
thereafter rapidly diminished.
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Figure 16. Comparison o f a) contrast volume and b) edema volume induced by PDT and
PCI at a light fluenee o f 2.5 J. The animals received 1 mg/kg AlPcSia- The PCI group of
animals also received an i.p. injection o f C lp at a concentration o f 1:50. The n values
listed above each data set indicate the number o f animals used to generate the
corresponding data bars.

The second comparison between PCI and PDT effects on the BBB was performed
using a light fluenee o f 1 J and a C l p prototoxin concentration o f 1:100 (Figure 17). In
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this case, the contrast and edema volumes induced by PCI were significantly greater than
those resulting from PDT. A direct comparison of Tl-weighted post contrast MRI scans
of two animals that received PDT and PCI treatments is shown in Figures 18 a and b,
respectively. The images clearly demonstrate the PCI effect on the BBB using this
combination of light fluenee and prototoxin concentration.
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Figure 17. Comparison of a) contrast volume and b) edema volume induced by PDT and
PCI (i.p.) at a light fluenee of 1 J. The animals received 1 mg/kg AlPcS 2 a- The PCI group
of animals also received an i.p. injection of C lp at a concentration of 1:100. The n values
listed above each data set indicate the number of animals used to generate the
corresponding data bars.
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Figure 18. Comparison of Tl-w eighted post contrast MRI scans after PDT and PCI
treatment, a) The PDT treated animal received a light fluenee o f 1 J; b) the PCI treated
animal received a light fluenee o f I J and an i.p. injection o f C lp at a concentration o f
1:100. Both animals were scanned on days I, 3, 5 and 18 after treatment. All TI post
contrast images were taken 15 minutes following i.p. contrast injection.

The effect o f prototoxin administration route was investigated in a series o f animals
receiving C lp prototoxin (1:50) i.e. and subjected to a light fluenee o f I J. As shown in
Figure 19, intracranial C lp administration produced much lower edema and contrast
volumes compared to i.p. administration. In fact, the volumes o f both i.e. PCI-induced
edema and contrast enhancement were similar to those observed for PDT.
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Figure 19. Comparison o f a) contrast volume and b) edema volume induced by PDT, PCI
(i.e.) and PCI (i.p.) at a light fluenee o f 1 J. The animals received 1 mg/kg AlPcSza- The
PCI (i.e.) group o f animals also received an i.c injection o f C l p aXa concentration of 1:50.
The PCI (i.p.) group o f animals also received an i.p. injection o f C l p ai a concentration
o f 1:100. The n values listed above each data set indicate the number o f animals used to
generate the corresponding data bars.

60

The last comparison between PCI and PDT effects on the BBB was performed at a
light fluenee of 0.5 J as shown in Figure 20. Both contrast and edema volumes induced
by PDT and PCI at this fluenee level were minimal suggesting only a slight degree of
BBB disruption.
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Figure 20. Comparison o f a) contrast volume and b) edema volume induced by PDT and
PCI at a light fluenee of 0.5 J. The animals received 1 mg/kg AlPcSia- The PCI group of
animals also received an i.p. injection o f C /p at a concentration o f 1:100. The n values
listed above each data set indicate the number o f animals used to generate the
corresponding data bars.
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CHAPTER 4

DISCUSSION
A previous study has demonstrated that ALA-mediated PDT was highly effective in
opening the BBB in a limited region o f the normal rat brain (Hirschberg et al., 2008).
Results o f the present study show that AlPcSia is a more potent photosensitizer as
evidenced by increased mortality (Figure 11) and contrast enhancement (Figure 12)
following relatively low light fluenees. The increased effectiveness o f AlPcS 2 a-PDT in
opening the BBB is most likely due to the site o f localization o f the photosensitizer. Since
AlPcS 2 a is an amphiphilic molecule it accumulates in cellular membranes such as those o f
the endothelial cells which constitute the BBB. Therefore, AlPcS 2 a-PDT causes direct
photochemical damage to cell membranes which can lead to disruption o f the BBB. In
contrast, ALA is a hydrophilic molecule that tends to accumulate in cellular organelles
such as the mitochondria. As a result, ALA-PDT is less likely to produce a direct effect
on the BBB.
The high mortality observed following interstitial AlPcS 2 a-PDT is not only due to the
preferential localization o f AlPcS 2 a to the BBB, but also due to the light distribution
associated with this mode o f light delivery. A previous study (Angell-Peterson et al.,
2007) demonstrated that the light fluenee rate at the tip o f an optical fiber inserted
directly into the rat brain was 100% higher than the actual power output. A rapid decrease
in the interstitial fluenee rate was observed with a light penetration depth o f about 6 mm
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in the rat brain. Surface irradiation was chosen in order to avoid the high fluenee rates
associated with interstitial light delivery and, as shown in Figure 11, this method of light
delivery was well tolerated.
In addition to the light delivery method, the degree o f BBB disruption induced by
AlPcSza-PDT was also found to be sensitively dependent on the photosensitizer
concentration and light fluenee level (Figures 13 and 14). The data show that reductions
in AlPcSza and/or light fluenee results in less damage to the BBB.
The data presented in Figure 15 show that the choice o f Cl p delivery has a profound
effect on animal survival. No direct evidence o f toxicity to the brain was observed
following intracranial injections o f relatively high C lp concentrations. Since the distance
o f drug diffusion through i.c. injection is extremely short, the potential toxicity o f C l p is
limited to a very small and localized region o f the brain, which is not enough to cause any
serious effect in the animal even with a relatively high drug concentration. In contrast, the
survival o f animals administered i.p. injections o f C lp was sensitively related to the drug
concentration. Since i.p. delivery is systemic, many critical organs (e.g. liver, kidney,
intestines, brain) will be exposed to the prototoxin. Therefore, the high mortality rates
observed following high doses o f C l p (Figure 15) was likely due to massive organ failure.
Overall, the results suggest that Cl p dilutions o f 1:100 can be administered safely in
Fischer rats.
Although the risk associated with i.p. delivery is greater than that observed following
i.c. administration, i.p. delivery is clearly more effective. The data presented in Figure 19
show that the effects on the BBB, as evidenced by edema and contrast volumes, were
similar for PDT and PCI with i.c. delivery o f Cl p. The ineffectiveness o f i.c. delivery is
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due to a number o f factors. First, the short diffusion distances o f macromolecules such as
C lp limit treatment volumes to short distances from the injection site. Second, within the
prototoxin diffusion volume, only a small fraction of Cl p molecules are likely to end up
in the brain vasculature and, hence be taken up by the endothelial cells via endocytosis.
Cl p molecules remaining in the extravascular space have little chance to make it back to
the endothelial cells due to the special structure o f the BBB.
The data presented in Figure 16 show that both high light fluenee (2.5 J) PDT and
PCI resulted in significant BBB disruption. Since significant differences between PCI and
PDT-induced edema and contrast volumes were not observed, the effects on the BBB
were attributed primarily to the PDT effect in the case o f both treatments. In contrast,
following a light fluenee of 1 J, significant differences in both contrast (Figure 17 a) and
edema (Figure 17 b) volumes were observed. This was taken to be indicative o f a PCI
effect. At the lowest light fluenee investigated (0.5 J), the data suggest that there was no
PCI effect (Figure 20): both PDT and PCI treatments resulted in minimal edema and
contrast volumes. Collectively, the data presented in Figures 16, 17 and 20 suggest that
the PCI effect is confined to a very narrow range o f light fluenees and therefore the
choice o f this parameter is critical for effective PCI.
A likely reason for the failure of high fluenee PCI is the generation o f high
concentrations o f singlet oxygen leading to photochemical damage o f endosome
encapsulated Cl p. Conversely, in the case o f the low light fluenee, the concentration of
singlet oxygen generated in the vesicle membrane was likely insufficient to induce
serious photochemical damage to this structure thus preventing the release o f Cl p. In
both cases, the biological effects o f Cl p were compromised thus leading to a significant
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diminution of the PCI effect on the BBB. With an optimal light fluenee o f 1 J, a sufficient
level o f PDT-induced photochemical damage resulted in the disruption o f the vesicle
membrane and release o f the Cl p molecules capable o f exerting their toxic effects on the
BBB.
PCI is a multi-step procedure and, in addition to light fluenee, this therapeutic
modality requires exquisite timing for optimal effect. First, the timing between
photosensitizer administration and prototoxin delivery is critical: a sufficient amount o f
AlPcS 2 a must be present in endothelial cells o f the target region prior to Cl p injection. If
the time interval is too short, the concentration o f photosensitizer in the plasma
membranes may be insufficient. Similarly, long time intervals may result in the clearance
o f photosensitizer prior to prototoxin administration. Previous animal studies suggest that
a 48 h interval is sufficient. Second, the timing between prototoxin administration and
light irradiation is also important. If the interval is too short, the number o f endosomeencapsulated Cl p molecules will be insufficient for the PCI effect. Conversely, a long
time interval increases the likelihood that Cl ^-laden endosomes will be captured by
lysosomes resulting in degradation o f the prototoxin. The results o f other investigators
suggest that time intervals between 1 and 4 h are sufficient.
In comparison with the osmotic opening method of BBB disruption described in
section 1.3.3, the biggest advantage o f the PCI effect on the BBB is its selectivity. The
osmotic opening method involves the administration o f a hypertonic solution (e.g.
mannitol) to cause shrinkage o f the endothelial cells resulting in the disruption o f tight
junctions and non-selective opening o f the BBB. This global disruption o f the BBB is
problematic because it allows passage o f a wide variety of molecules into the brain. Even
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though an i.p. injection o f C lp prototoxin was used in the PCI procedure, and this
injection method can lead to a global distribution o f prototoxin, the low concentration o f
prototoxin used (1:100 dilution) was unable to cause BBB damage by itself due to
lysosomal degradation o f C lp molecules trapped in endocytic vesicles. The cytotoxic
effect o f Cl p on the BBB is limited to regions o f the brain exposed to proper light
fluenees.
Both PDT and PCI treatments were able to induce a localized BBB disruption in a
timely manner. The extent o f BBB disruption on different days after PDT or PCI
treatment demonstrated a very similar pattern, o f which the peak opening appeared to be
on day 3 and the disruption was then gradually restored and diminished to the baseline
about 18 days after treatment. However, the most important advantage o f PCI over PDT
is its high efficiency for inducing BBB disruption. As shown in Figures 17 and 18, when
using equivalent light fluenees o f I J, the PCI effect induced a much greater extent of
BBB disruption than PDT. In other words, in order to achieve similar effects on the BBB,
higher light fluenees are required for PDT compared to PCI. Unfortunately, higher light
fluenees increase the potential for edema formation and hence, morbidity and mortality.
Therefore, under the appropriate conditions, PCI would appear to be a safe alternative to
PDT for selective disruption of the BBB.
The results o f the present study suggest that, under the appropriate conditions, PCI is
a safe and efficient method for the selective disruption o f the BBB in rats. Due to Cl p
toxicitiy, and the lack of evidence for the existence o f specific receptor sites for Cl p on
human brain endothelial membranes, it is highly unlikely that Cl /i-based PCI approaches
will be used in human BBB studies. Nevertheless, the results o f the present study provide
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the basis for further PCI studies using non-toxic vasoactive compounds including
bradykinin, leukotrienes and histamine. For example, a number o f studies have shown
that bradykinin can selectively open the abnormal BBB resulting in an increase in the
permeability to both low and high molecular weight neuropharmaceutical agents
(Matsukado et al., 1998). Whether these non-toxic agents can be used in the PCI
technique to potentiate BBB disruption remains to be shown.
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CHAPTER 5

CONCLUSIONS
The PCI effect in normal Fischer rat brain was found to be sensitively dependent on
light fluence, photosensitizer concentration, C l p prototoxin concentration and
administration route. Selective disruption o f the BBB, as determined from MR
evaluations o f edema and contrast volumes was observed for i.p. administrations of 1:100
stock dilutions of C l p prototoxin and photosensitizer concentrations and light fluences of
1 mg/kg and 1 J respectively. The extent of BBB disruption after PCI treatment increased
to its peak level by day 3 and then gradually decreased; the disruption was seen to be
restored by day 18.
The aim o f future studies will be to improve the PCI method for BBB disruption. First,
it is necessary to modify the light delivery method from surface to interstitial irradiation
since surface irradiation significantly limits access to various treatment locations due to
the short penetration of light in brain tissues. As illustrated in the present work, the main
limitation associated with interstitial light delivery is the increased likelihood of edemainduced morbidity and mortality due to high light fluences near the light source.
Therefore, additional experiments investigating lower AlPcSza concentrations, fluence
rates and fluences are required in order to optimize interstitial AlPcSza-PDT. Second,
finding a non-toxic agent capable of disrupting the BBB is a requirement for clinical
trials.
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The ultimate goal of selective and reversible opening o f the BBB is to mitigate the
passage o f anti-cancer drugs across the barrier in order to target infiltrating glioma cells.
With this goal in mind, animal studies involving Fischer rats with orthotopic gliomas
should be initiated. As a starting point, optimum parameters determined in the present
study could be used to selectively disrupt the BBB in rat brains implanted with
infiltrating glioma cells. Following administration o f a chemotherapeutic agent, animal
survival could be compared to non-PCI and chemotherapy-only control animals. In
principle, these types of experiments could be extended to evaluate the efficacy of PCI
for the treatment o f a wide variety o f neurological diseases using disease specific
therapeutic agents.
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